Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT)'s Joe Wiley talks to Proactive London's Katie Pilbeam after reporting revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%.
Revenue rose to US$56.5mln in the three months to end-September from US$49.3mln in the same period last year.
Much of this performance is down to Metreleptin where revenues rocketed by 21.5% to US$36.3mln in the third quarter. Excluding Latin America, where ordering has been sporadic, sales of the drug were 51.6% higher.
Underlying profits (EBITDA before restructuring and acquisition costs) totalled US$6.2mln. Excluding costs related to the acquisition of Chiasma in August, this was the 7th consecutive quarter of positive EBITDA generation Joe points out.